Bridge City Capital LLC Increases Stake in Amphastar Pharmaceuticals

Summary

Bridge City Capital LLC increased its holdings in Amphastar Pharmaceuticals, Inc. by 65.3% in the first quarter, now holding 115,855 shares valued at $3.36 million. Other hedge funds have also increased their holdings, and 65.09% of the stock is held by institutional investors. Analysts have mixed ratings for Amphastar, with an average target price of $32.33. The stock opened at $25.99, within a 52-week range of $22.64 to $53.96.Market Beat

Impact Analysis

This event is classified at the company level as it specifically pertains to Bridge City Capital LLC’s investment in Amphastar Pharmaceuticals. The increase in holdings suggests a positive outlook from institutional investors toward Amphastar, which can influence other investors’ perceptions and potentially drive up the stock price. However, mixed analyst ratings indicate uncertainty about future performance. Immediate market reactions might include increased trading activity and short-term price fluctuations. Investors should consider the risks of price volatility and assess the stock’s potential to reach the average target price. Opportunities include leveraging Amphastar’s current valuation against analyst expectations.Market Beat